STOCK TITAN
  1. Home
  2. SEC Filings
  3. TRDA
  4. [Form 4] Entrada Therapeutics, Inc. Insider Trading Activity

Entrada holder MPM funds sell 86K shares

Filing Impact
(Neutral)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
4

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. (TRDA) had affiliated investment funds jointly report open-market or private sales of a total of 86,482 shares of common stock on September 1–3, 2026, at weighted average prices of about $7.06, $7.19 and $7.17 per share, all held indirectly through MPM BioVentures entities, which each reporting person disclaims beneficial ownership of except for its pecuniary interest.

Insider MPM BioVentures 2014, L.P., EVNIN LUKE, GADICKE ANSBERT, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Sold 86,482 shs ($617K)
Type Security Shares Price Value
Sale Common Stock F8, F9, F4, F10 32,263 $7.17 $231K
Sale Common Stock F5, F6, F4, F7 25,131 $7.19 $181K
Sale Common Stock F1, F2, F3, F4 29,088 $7.06 $205K
Holdings After Transaction: Common Stock — 4,144,952 shares (Indirect, See Footnote)
Footnotes (10)
  1. F1. The shares were sold as follows: 13,208 by MPM BioVentures 2014, L.P. ("BV 2014"), 881 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 455 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,556 by MPM BioVentures 2018, L.P. ("BV 2018"), 720 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 268 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
  2. F2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.80 to $7.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  3. F3. The shares are held as follows: 1,908,217 by BV 2014, 127,274 by BV 2014(B), 65,681 by AM BV2014, 1,958,433 by BV 2018, 104,089 by BV 2018(B) and 38,652 by AM BV2018.
  4. F4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  5. F5. The shares were sold as follows: 11,412 by BV 2014, 761 by BV 2014(B), 393 by AM BV2014, 11,712 by BV 2018, 622 by BV 2018(B) and 231 by AM BV2018.
  6. F6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.9601 to $7.3273 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  7. F7. The shares are held as follows: 1,896,805 by BV 2014, 126,513 by BV 2014(B), 65,288 by AM BV2014, 1,946,721 by BV 2018, 103,467 by BV 2018(B) and 38,421 by AM BV2018.
  8. F8. The shares were sold as follows: 14,650 by BV 2014, 977 by BV 2014(B), 504 by AM BV2014, 15,036 by BV 2018, 799 by BV 2018(B) and 297 by AM BV2018.
  9. F9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0434 to $7.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  10. F10. The shares are held as follows: 1,882,155 by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B) and 38,124 by AM BV2018.
Total shares sold 86,482 shares Aggregate TRDA common stock sales on September 1–3, 2026 by affiliated funds
Shares sold September 1, 2026 29,088 shares Common stock sale reported as indirect ownership
Weighted average sale price September 1, 2026 $7.06 per share Common stock sales with price range from $6.80 to $7.15 per share
Shares sold September 2, 2026 25,131 shares Common stock sale reported as indirect ownership
Weighted average sale price September 2, 2026 $7.19 per share Common stock sales with price range from $6.9601 to $7.3273 per share
Shares sold September 3, 2026 32,263 shares Common stock sale reported as indirect ownership
Weighted average sale price September 3, 2026 $7.17 per share Common stock sales with price range from $7.0434 to $7.405 per share
BV 2014 holdings after September 3, 2026 1,882,155 shares Common stock of Entrada Therapeutics, Inc. held by BV 2014
ten percent owner regulatory
"each identified as a ten percent owner with respect to Entrada"
weighted average sale price financial
"Price represents the weighted average sale price of the shares sold"
beneficial ownership regulatory
"Each Reporting Person disclaims beneficial ownership of the securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his or its respective pecuniary interest"
indirect ownership regulatory
"Common stock sale reported as indirect ownership"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who are the reporting persons in TRDA’s latest Form 4?
The filing lists multiple MPM BioVentures-affiliated entities, including MPM BioVentures 2014, L.P. and related funds and LLCs, plus individuals Luke Evnin, Ansbert Gadicke and Todd Foley, each identified as a ten percent owner with respect to Entrada Therapeutics, Inc.

How many TRDA shares were sold in this Form 4, and on which dates?
Affiliated entities reported selling a total of 86,482 shares of Entrada Therapeutics common stock: 29,088 shares on September 1, 2026, 25,131 shares on September 2, 2026, and 32,263 shares on September 3, 2026.

What prices were received for the TRDA shares sold in this Form 4?
The reported sales were made at weighted average prices of about $7.06 per share on September 1, $7.19 per share on September 2, and $7.17 per share on September 3, 2026, with price ranges from roughly $6.80 to $7.41 per share as disclosed in the footnotes.

Are the TRDA shares held directly or indirectly by the reporting persons?
All reported TRDA shares are held indirectly through various MPM BioVentures partnerships and LLCs. A footnote states that each reporting person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest.

How many TRDA shares did key MPM funds hold after the last reported sale?
After the September 3, 2026 transactions, the footnotes state holdings of 1,882,155 shares by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B), and 38,124 by AM BV2018.

Were the TRDA share sales made under a Rule 10b5-1 trading plan?
No. The document-level indicator shows the Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes describing the September 1–3, 2026 transactions do not state that they were made pursuant to a Rule 10b5-1 trading plan.

Are there any TRDA derivative securities reported in this Form 4?
No. The filing’s derivative section is empty, and the summary for derivatives shows no derivative transactions and no remaining derivative positions reported in connection with these September 2026 common stock sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MPM BioVentures 2014, L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/01/2026S29,088(1)D$7.06(2)4,202,346ISee Footnote(3)(4)
Common Stock09/02/2026S25,131(5)D$7.19(6)4,177,215ISee Footnote(4)(7)
Common Stock09/03/2026S32,263(8)D$7.17(9)4,144,952ISee Footnote(4)(10)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
MPM BioVentures 2014, L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
EVNIN LUKE
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
GADICKE ANSBERT
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Foley Todd
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BioVentures 2014 (B), L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM Asset Management Investors BV2014 LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BioVentures 2014 LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BioVentures 2014 GP LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BIOVENTURES 2018 (B), L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. The shares were sold as follows: 13,208 by MPM BioVentures 2014, L.P. ("BV 2014"), 881 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 455 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,556 by MPM BioVentures 2018, L.P. ("BV 2018"), 720 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 268 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.80 to $7.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
3. The shares are held as follows: 1,908,217 by BV 2014, 127,274 by BV 2014(B), 65,681 by AM BV2014, 1,958,433 by BV 2018, 104,089 by BV 2018(B) and 38,652 by AM BV2018.
4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
5. The shares were sold as follows: 11,412 by BV 2014, 761 by BV 2014(B), 393 by AM BV2014, 11,712 by BV 2018, 622 by BV 2018(B) and 231 by AM BV2018.
6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.9601 to $7.3273 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
7. The shares are held as follows: 1,896,805 by BV 2014, 126,513 by BV 2014(B), 65,288 by AM BV2014, 1,946,721 by BV 2018, 103,467 by BV 2018(B) and 38,421 by AM BV2018.
8. The shares were sold as follows: 14,650 by BV 2014, 977 by BV 2014(B), 504 by AM BV2014, 15,036 by BV 2018, 799 by BV 2018(B) and 297 by AM BV2018.
9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0434 to $7.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
10. The shares are held as follows: 1,882,155 by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B) and 38,124 by AM BV2018.
Remarks:
See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.
/s/ Ansbert Gadicke09/03/2026
/s/ Luke Evnin09/03/2026
/s/ Todd Foley09/03/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014 (B), L.P.09/03/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC09/03/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC09/03/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018 (B), L.P.09/03/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC09/03/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P.09/03/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the manager of MPM Asset Management Investors BV2018 LLC09/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on TRDA

All TRDA news

Trending in the feed

EDBL
Edible Garden Announces Commercial Supply Agreement and Strategic Partnership with Caney Fork Farms Open the live feed